1
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


3

4
Kevin Rodzinak
Vadim Y Dudkin, Mark E Fraley, Kenneth L Arrington, Mark E Layton, Alexander J Reif, Kevin J Rodzinak, Joseph E Pero: Positive allosteric modulators of MGLUR2. Merck Sharp & Dohme, Keith D MacMillan, John C Todaro, March 31, 2015: US08993779 (1 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


5
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


6
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


7
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of akt activity. December 29, 2011: US20110319443-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


8
Kevin Rodzinak
Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J Rodzinak, Toshihiro Sakamoto, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activity. April 21, 2011: US20110092511-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


9
Kevin Rodzinak
Mark E Layton, Kevin J Rodzinak, Michael J Kelly, Philip E Sanderson: 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists. Merck And Co, December 20, 2007: US20070293515-A1

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, ...


10
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...



Click the thumbnails below to visualize the patent trend.